Author

Adila Izgutdina

University of California, San FranciscoORCID 0000-0002-3296-3261Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Amrik S. KangiD· 2 shared Arun P. WiitaiD· 2 shared Fernando Salangsang· 2 shared Juan A. CámaraiD· 2 shared Paul J. Phojanakong· 2 shared Veronica SteriiD· 2 shared Aaron C. LoganiD· 1 shared Akul Naik· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Amrik S. KangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies

Adila Izgutdina, Tasfia Rashid, William C. Temple, Sarah Aminov, Bonell Patiño-Escobar, Sujata B. Walunj, Huimin Geng, Hiroyuki Takamatsu, Daniel Gil-Alós, Amrik S. Kang, Emilio Ramos, Szu‐Ying Chen, Haley Johnson, Matthew A. Nix, Akul Naik, , Arun P. Wiita

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

Journal for ImmunoTherapy of Cancer · Dec 1, 2025Peer-reviewedImmunology

Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia

Amrik S. Kang, H. A. Johnson, Nicole Lei, Jeremiah Wong, Nabeel Razi, Adila Izgutdina, Corynn Kasap, Nikhil Chilakapati, Jose M. Rivera, Paul J. Phojanakong, Juan A. Cámara, Fernando Salangsang, Veronica Steri, Aaron C. Logan, Justin Eyquem, , Arun P. Wiita

This paper develops dual-antigen targeting CAR-T cells against CD70 and active integrin β2 to overcome AML antigen heterogeneity and reduce off-tumor toxicity.

bioRxiv · Sep 21, 2025 · PreprintImmunology